Hester Biosciences Ltd

- Majority of the existing capex for ongoing projects has been completed; remaining expenditure is not expected to be significant as per CFO Nikhil Jhanwar. - Current focus is on regulatory approvals for completed capacity expansion, which will double overall vaccine manufacturing capacity. - The BSL-3 laboratory, initially for COVID vaccine production, is being repurposed for other vaccines (human/animal) with nominal additional spend estimated to be around INR 0.5 to 2 crores. - No significant new capital investment planned unless new projects arise. - Company is working on four new vaccine developments, leveraging existing infrastructure. - Strategic investment includes expanding into African markets despite short-term challenges, with backing from the Bill & Melinda Gates Foundation.

- Animal Healthcare division is growing rapidly, now contributing 42% to the top line, up from 30% last year, driven by increased vaccine sales (e.g., PPR and LSD vaccines). - Vaccine business expected to increase as a percentage, though larger health products market will require more focus on health products for scale-up. - LSD immunization in India seen as repeatable business with annual vaccination; potential market linked to 9 crore cattle vaccinated recently. - African market growth is delayed due to economic and regulatory challenges but expected to pick up in 6-8 months; presence there positions Hester advantageously for future demand. - New generation vaccines (e.g., next-gen Brucella, Classical Swine Fever, Lumpy Skin Disease) under development to drive future growth. - Sales in pharma/trading products are currently one-time but could recur. - Overall revenue growth supported by expanded sales force and wider product reach.

- Hester Biosciences is focused on achieving significant growth, targeting INR500 crores in the next 2–3 years. - The animal healthcare division is growing rapidly, now contributing 42% to the top line, expected to increase further. - Expansion in Africa is expected to pick up within 6–8 months despite current delays due to economic and regulatory hurdles. - Vaccine sales, especially PPR and LSD, are planned to increase with stable production capacity; LSD immunization is now a repeat annual business. - Health product sales in poultry are rising, balancing margins despite lower vaccine sales. - New vaccine developments (Brucella, Classical Swine Fever, Sheep Pox, Lumpy Skin Disease, Avian Influenza) aim to boost future revenues. - Operating margins are expected to stabilize with improved product mix; animal health products have better ROI than vaccines. - One-time pharma product sales have boosted recent gross margins but are not expected to be recurring. - Overall, Hester commits to working hard for sustainable long-term profitability and growth.

- PPR vaccine expected sales from current quarter till end of supply: Approximately INR 35 crores (around INR 3 crores per month) (Page 6). - LSD vaccine doses expected: 5 to 6 crore doses over next three quarters, translating to INR 30 to 45 crores revenue (Page 11). - PPR vaccine quantity expected: 30 crore doses post-24 quarters, translating to INR 45 crores revenue (Page 11). - Challenges include funding issues in countries like Nepal and Africa due to economic constraints and regulatory delays (Pages 7, 15). - Africa market facing slow pick-up; management estimates 6-8 months for recovery and better sales flow (Page 7). - No significant capex expected; existing projects are mostly complete and in regulatory approval (Page 11). - Positive trend observed with planned government immunization campaigns supporting order inflows (Pages 8-9, 15).

- No significant new capital expenditure (capex) is expected on existing projects; majority of expenditure is already done, currently in regulatory approval stage. - No mention of new fundraising through debt or equity for ongoing projects; the company feels well-covered financially for current projects. - Any new projects requiring finances would be separately addressed; currently, no such announcements. - Repurposing existing BSL-3 facility for vaccines will require nominal spend (estimated up to a couple of crores INR, possibly less than 50 lakhs INR), implying limited need for fresh funds. - Overall, no indication of immediate or planned fundraising through debt or equity as per the current transcript.